U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H25N3O4
Molecular Weight 443.4944
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LUCITANIB

SMILES

CNC(=O)C1=C2C=CC(OC3=CC=NC4=CC(OCC5(N)CC5)=C(OC)C=C34)=CC2=CC=C1

InChI

InChIKey=CUDVHEFYRIWYQD-UHFFFAOYSA-N
InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)

HIDE SMILES / InChI

Molecular Formula C26H25N3O4
Molecular Weight 443.4944
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800031368 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/e9507053dd36cb9217816ffb566c8720.html | https://www.ncbi.nlm.nih.gov/pubmed/25193991

Lucitanib (E-3810) is a novel multi-kinase inhibitor currently in clinical trials for its anti-angiogenic and anti-tumor activity. A Phase I/IIa clinical trial of lucitanib was initiated in 2010 and has demonstrated multiple objective responses in FGFR1 gene-amplified breast cancer patients, and objective responses were also observed in patients with tumors often sensitive to VEGFR inhibitors, such as renal cell and thyroid cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR alpha-beta). The most common adverse events were hypertension, asthenia, and proteinuria.

Approval Year

Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity. Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability.
Route of Administration: Oral
the recovery of VEGFR2 phosphorylation after AL3810 washout was examined in HUVEC cells. Treatment with 1 uM/L of AL3810 for 4 hrs caused a dramatic decrease in the level of phospho-VEGFR2. Upon the removal of the inhibitor, VEGFR2 phosphorylation was recovered substantially at 6 hrs, followed by a total restoration at 24 hrs after inhibitor washout, indicating that AL3810 is a reversible inhibitor.
Substance Class Chemical
Created
by admin
on Sat Dec 16 04:16:12 UTC 2023
Edited
by admin
on Sat Dec 16 04:16:12 UTC 2023
Record UNII
PP449XA4BH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LUCITANIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
E-3810
Code English
LUCITANIB [USAN]
Common Name English
Lucitanib [WHO-DD]
Common Name English
lucitanib [INN]
Common Name English
S-80881
Code English
1-NAPHTHALENECARBOXAMIDE, 6-((7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXY-4-QUINOLINYL)OXY)-N-METHYL-
Systematic Name English
6-({7-[(1-Aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-N-methylnaphthalene-1-carboxamide
Systematic Name English
S80881
Code English
CO-3810
Code English
AL-3810
Code English
Classification Tree Code System Code
NCI_THESAURUS C93259
Created by admin on Sat Dec 16 04:16:12 UTC 2023 , Edited by admin on Sat Dec 16 04:16:12 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID30147356
Created by admin on Sat Dec 16 04:16:12 UTC 2023 , Edited by admin on Sat Dec 16 04:16:12 UTC 2023
PRIMARY
DRUG BANK
DB11845
Created by admin on Sat Dec 16 04:16:12 UTC 2023 , Edited by admin on Sat Dec 16 04:16:12 UTC 2023
PRIMARY
SMS_ID
100000174849
Created by admin on Sat Dec 16 04:16:12 UTC 2023 , Edited by admin on Sat Dec 16 04:16:12 UTC 2023
PRIMARY
NCI_THESAURUS
C95726
Created by admin on Sat Dec 16 04:16:12 UTC 2023 , Edited by admin on Sat Dec 16 04:16:12 UTC 2023
PRIMARY
INN
9581
Created by admin on Sat Dec 16 04:16:12 UTC 2023 , Edited by admin on Sat Dec 16 04:16:12 UTC 2023
PRIMARY
FDA UNII
PP449XA4BH
Created by admin on Sat Dec 16 04:16:12 UTC 2023 , Edited by admin on Sat Dec 16 04:16:12 UTC 2023
PRIMARY
ChEMBL
CHEMBL2220486
Created by admin on Sat Dec 16 04:16:12 UTC 2023 , Edited by admin on Sat Dec 16 04:16:12 UTC 2023
PRIMARY
WIKIPEDIA
Lucitanib
Created by admin on Sat Dec 16 04:16:12 UTC 2023 , Edited by admin on Sat Dec 16 04:16:12 UTC 2023
PRIMARY
CAS
1058137-23-7
Created by admin on Sat Dec 16 04:16:12 UTC 2023 , Edited by admin on Sat Dec 16 04:16:12 UTC 2023
PRIMARY
USAN
CD-41
Created by admin on Sat Dec 16 04:16:12 UTC 2023 , Edited by admin on Sat Dec 16 04:16:12 UTC 2023
PRIMARY
PUBCHEM
25031915
Created by admin on Sat Dec 16 04:16:12 UTC 2023 , Edited by admin on Sat Dec 16 04:16:12 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY